Pharming Group NV (PHAR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $891.80M
Last updated: Nov 17, 2026 at 11:03 AM ET
Pharming Group NV (PHAR) P/E Ratio & Valuation History
Pharming Group NV (PHAR) trades at 39.3x trailing earnings and 2.4x sales. Its P/S of 2.4x is below its 5-year median of 3.5x. Its forward P/E is 263.2x. The median P/E across 3 similar companies is 14.2x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 85.1% lower over the next year. Its free cash flow yield is 3.4%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 39.3x |
| Forward P/E | 263.2x |
| Price to sales | 2.4x |
| Price to book | 3.2x |
| EV/EBITDA | 15.2x |
| Price to FCF | 29.7x |
| EV/FCF | 26.9x |
| PEG | N/A |
| FCF yield | 3.4% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.4x | 3.5x | N/A |
| P/B | 3.2x | 4.2x | N/A |
Valuation History
Over the 3 of the 6 year ends shown that have a P/E, its P/E ranged from 39.9x in 2021 to 252.4x in 2025.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $17.67 | 252.4x | 3.3x | 4.8x |
| 2024 | $10.07 | N/A | N/A | 31.0x |
| 2023 | $11.43 | N/A | 5.0x | 35.0x |
| 2022 | $11.03 | N/A | 4.4x | 3.8x |
| 2021 | $8.94 | 39.9x | 3.5x | 3.7x |
| 2020 | $15.20 | 97.9x | 6.0x | 8.9x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PHAR
What is PHAR's forward P/E ratio?
Pharming Group NV has a forward P/E ratio of 263.2x.
Is PHAR stock overvalued?
GNG's valuation label for PHAR is Undervalued. Its P/E of 39.3x compares with a median of 14.2x across 3 similar companies.
What is PHAR's price to sales ratio?
Pharming Group NV has a price to sales ratio of 2.4x.
PHAR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors